224 related articles for article (PubMed ID: 29956478)
1. In Vitro Screening of Six Protein Kinase Inhibitors for Time-Dependent Inhibition of CYP2C8 and CYP3A4: Possible Implications with regard to Drug-Drug Interactions.
Filppula AM; Mustonen TM; Backman JT
Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):739-748. PubMed ID: 29956478
[TBL] [Abstract][Full Text] [Related]
2. In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors.
Filppula AM; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2014 Jul; 42(7):1202-9. PubMed ID: 24713129
[TBL] [Abstract][Full Text] [Related]
3. Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A
Paludetto MN; Kurkela M; Kahma H; Backman JT; Niemi M; Filppula AM
Drug Metab Dispos; 2023 Mar; 51(3):293-305. PubMed ID: 36446607
[TBL] [Abstract][Full Text] [Related]
4. Pathway-dependent inhibition of paclitaxel hydroxylation by kinase inhibitors and assessment of drug-drug interaction potentials.
Wang Y; Wang M; Qi H; Pan P; Hou T; Li J; He G; Zhang H
Drug Metab Dispos; 2014 Apr; 42(4):782-95. PubMed ID: 24476576
[TBL] [Abstract][Full Text] [Related]
5. Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates.
Filppula AM; Laitila J; Neuvonen PJ; Backman JT
Br J Pharmacol; 2012 Apr; 165(8):2787-98. PubMed ID: 22014153
[TBL] [Abstract][Full Text] [Related]
6. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
Prueksaritanont T; Ma B; Tang C; Meng Y; Assang C; Lu P; Reider PJ; Lin JH; Baillie TA
Br J Clin Pharmacol; 1999 Mar; 47(3):291-8. PubMed ID: 10215754
[TBL] [Abstract][Full Text] [Related]
7. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M
Clin Pharmacokinet; 2017 Apr; 56(4):409-420. PubMed ID: 27599706
[TBL] [Abstract][Full Text] [Related]
8. Screening of 16 major drug glucuronides for time-dependent inhibition of nine drug-metabolizing CYP enzymes - detailed studies on CYP3A inhibitors.
Kahma H; Paludetto MN; Neuvonen M; Kurkela M; Filppula AM; Niemi M; Backman JT
Eur J Pharm Sci; 2024 Jul; 198():106735. PubMed ID: 38423227
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of sanguinarine on human liver cytochrome P450 enzymes.
Qi XY; Liang SC; Ge GB; Liu Y; Dong PP; Zhang JW; Wang AX; Hou J; Zhu LL; Yang L; Tu CX
Food Chem Toxicol; 2013 Jun; 56():392-7. PubMed ID: 23500771
[TBL] [Abstract][Full Text] [Related]
10. An automated cocktail method for in vitro assessment of direct and time-dependent inhibition of nine major cytochrome P450 enzymes - application to establishing CYP2C8 inhibitor selectivity.
Kahma H; Aurinsalo L; Neuvonen M; Katajamäki J; Paludetto MN; Viinamäki J; Launiainen T; Filppula AM; Tornio A; Niemi M; Backman JT
Eur J Pharm Sci; 2021 Jul; 162():105810. PubMed ID: 33753217
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):249-56. PubMed ID: 16176562
[TBL] [Abstract][Full Text] [Related]
12. In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450.
McCormick A; Swaisland H; Reddy VP; Learoyd M; Scarfe G
Xenobiotica; 2018 Jun; 48(6):555-564. PubMed ID: 28657402
[TBL] [Abstract][Full Text] [Related]
13. Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants.
Sechaud R; Gu H; Rahmanzadeh G; Taylor A; Chiparus O; Sharma GK; Breitschaft A; Menssen HD
Cancer Chemother Pharmacol; 2024 May; 93(5):439-453. PubMed ID: 38270613
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of gypenosides on seven human cytochrome P450 enzymes in vitro.
He M; Jiang J; Qiu F; Liu S; Peng P; Gao C; Miao P
Food Chem Toxicol; 2013 Jul; 57():262-5. PubMed ID: 23583485
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic In Vitro Studies Indicate that the Clinical Drug-Drug Interaction between Telithromycin and Simvastatin Acid Is Driven by Time-Dependent Inhibition of CYP3A4 with Minimal Effect on OATP1B1.
Elsby R; Hare V; Neal H; Outteridge S; Pearson C; Plant K; Gill RU; Butler P; Riley RJ
Drug Metab Dispos; 2019 Jan; 47(1):1-8. PubMed ID: 30348903
[TBL] [Abstract][Full Text] [Related]
16. Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response.
Filppula AM; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2013 Jan; 41(1):50-9. PubMed ID: 23028140
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
Gu H; Dutreix C; Rebello S; Ouatas T; Wang L; Chun DY; Einolf HJ; He H
Drug Metab Dispos; 2018 Feb; 46(2):109-121. PubMed ID: 29117990
[TBL] [Abstract][Full Text] [Related]
18. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.
Jaakkola T; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):44-51. PubMed ID: 16867170
[TBL] [Abstract][Full Text] [Related]
19. Reversible inhibition of three important human liver cytochrome p450 enzymes by tiliroside.
Sun DX; Lu JC; Fang ZZ; Zhang YY; Cao YF; Mao YX; Zhu LL; Yin J; Yang L
Phytother Res; 2010 Nov; 24(11):1670-5. PubMed ID: 21031626
[TBL] [Abstract][Full Text] [Related]
20. Use of Human Plasma Samples to Identify Circulating Drug Metabolites that Inhibit Cytochrome P450 Enzymes.
Eng H; Obach RS
Drug Metab Dispos; 2016 Aug; 44(8):1217-28. PubMed ID: 27271369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
